Collin C F, Friedrich C, Godbold J, Hajdu S, Brennan M F
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Semin Surg Oncol. 1988;4(1):30-7. doi: 10.1002/ssu.2980040108.
The charts of 423 patients with localized extremity soft-tissue sarcoma treated at our institution over a 10-year period (1968-1978) were reviewed. Data were subjected to both univariate and multivariate analysis, with independent variables in the multivariate analysis appearing in capital letters. Factors associated with an increased risk of local recurrence included the following: AGE greater than 53; PRESENTATION WITH RECURRENT DISEASE; HIGH TUMOR GRADE; positive regional nodes; TREATMENT BY LIMB-SPARING SURGERY (LSS); invasion of vital structures (LSS only); INADEQUATE MARGINS; and biopsy with delayed definitive resection. Survival was adversely affected by the following: AGE greater than 53; PAINFUL MASS; PROXIMAL SITE; SIZE greater than or equal to 10 cm; HIGH TUMOR GRADE; POSITIVE NODES; invasion of vital structures; TREATMENT BY AMPUTATION; INADEQUATE MARGINS; and local recurrence after treatment at our institution. Significant variations in both local recurrence and survival according to histopathology were also observed, with EMBRYONAL RHABDOMYOSARCOMA, ANGIOSARCOMA, and MALIGNANT PERIPHERAL NERVE TUMORS emerging as independent predictors of local recurrence. Using the Cox models for local recurrence and survival, patients were stratified into high-, intermediate-, and low-risk categories based on the presence or absence of each variable. Risk factor analysis should be part of the overall evaluation of each patient with extremity sarcoma.
回顾了我院在10年期间(1968 - 1978年)治疗的423例局限性肢体软组织肉瘤患者的病历。数据进行了单因素和多因素分析,多因素分析中的自变量用大写字母表示。与局部复发风险增加相关的因素包括:年龄大于53岁;复发性疾病表现;肿瘤分级高;区域淋巴结阳性;保肢手术(LSS)治疗;侵犯重要结构(仅LSS);切缘不充分;以及活检后延迟确定性切除。生存受到以下因素的不利影响:年龄大于53岁;疼痛性肿块;近端部位;大小大于或等于10 cm;肿瘤分级高;淋巴结阳性;侵犯重要结构;截肢治疗;切缘不充分;以及在我院治疗后局部复发。根据组织病理学观察到局部复发和生存均有显著差异,胚胎性横纹肌肉瘤、血管肉瘤和恶性周围神经肿瘤成为局部复发的独立预测因素。使用局部复发和生存的Cox模型,根据每个变量的存在与否将患者分为高、中、低风险类别。风险因素分析应作为每个肢体肉瘤患者全面评估的一部分。